Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Ocuphire Pharma Inc
R3X1Current price
1.04 EUR
+0.073 EUR (+7.45%)
Last closed
1.09 USD
Company
www.ocuphire.com
ISIN
US67577R1023
Sector
Healthcare
Industry
Biotechnology
Exchange
Frankfurt Exchange
Capitalization
31 737 184 USD
Yield for 12 month
-59.20 %
1Y
3Y
5Y
10Y
15Y
R3X1
Opus Genetics, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. The company offers Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as is in Phase III clinical trials for presbyopia and dim light or night vision disturbances. Its lead retinal product candidate is APX3330, a small-molecule inhibitor of reduction oxidation effector factor-1 protein that has completed Phase II clinical trial for the treatment of diabetic retinopathy. The company also develops APX2009 and APX2014 that are preclinical product candidates for retina indications. The company was formerly known as Ocuphire Pharma, Inc. Opus Genetics, Inc. was founded in 2018 and is headquartered in Farmington Hills, Michigan. Address: 37000 Grand River Avenue, Farmington Hills, MI, United States, 48335
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
13.67 USDP/E ratio
–Dividend Yield
–Current Year
+19 049 000 USD
Last Year
+39 850 000 USD
Current Quarter
+1 112 000 USD
Last Quarter
+1 711 000 USD
Current Year
+19 043 000 USD
Last Year
+39 846 000 USD
Current Quarter
+832 000 USD
Last Quarter
-3 038 000 USD
Key Figures R3X1
1 year
3 years
5 years
10 years
EBITDA
-15 072 000 USD
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-21.35 %
PEG Ratio
–
Return On Equity TTM
-36.01 %
Wall Street Target Price
13.67 USD
Revenue TTM
16 449 000 USD
Book Value
1.56 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
-69.7 %
Dividend Yield
–
Gross Profit TTM
-14 584 000 USD
Earnings per share
-0.54 USD
Diluted Eps TTM
-0.54 USD
Most Recent Quarter
II 2024
Quarterly Earnings Growth YOY
–
Profit Margin
-85.75 %
Dividend Analytics R3X1
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History R3X1
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
1:4
Payout Ratio
–
Last Split Date
06.11.2020
Dividend Date
06.11.2020
Stock Valuation R3X1
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
12.0048
Enterprise Value Revenue
0.1986
Price Sales TTM
1.9294
Enterprise Value EBITDA
-2.5497
Price Book MRQ
0.8664
Financials R3X1
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators R3X1
For 52 weeks
1.07 USD
3.4 USD
50 Day MA
1.27 USD
Shares Short Prior Month
1 095 057
200 Day MA
1.74 USD
Short Ratio
10.1
Shares Short
930 639
Short Percent
3.74 %
BeatStart